Advertisement

AbbVie Inc. ABBV

Set alert

Price alert · ABBV

All alert types
294.89 USD +4.10 +1.41%

At close · Oct 30

295.30 +0.41 +0.14%

After hours · Oct 30, 6:40 PM ET

Bid
294.50 × 200
Ask
294.89 × 100
291.01 Day range 298.74
197.38 52-week range 294.89
YTD
+29.06%
1 year
+29.22%
Open
292.00
Prev close
290.79
Mkt cap
521.11B
Vol
6.90M
Avg vol
4.72M
EPS
3.54
P/E
83.30
Div yield
2.38%
More statistics
Low
291.01
High
298.74
Forward P/E
18.15
Beta
0.23
Short ratio
3.22
Inst. own
77.38%
Dividend
6.92
Ex-div date
Oct 14, 2026
Earnings
Feb 3, 2027
50-d avg
268.63
200-d avg
236.73
1y target
283.19

5Y chart

Chart tools
Interval

Events in this range
  • Jan 13, 2022Dividend: 1.41
  • Apr 13, 2022Dividend: 1.41
  • Jul 14, 2022Dividend: 1.41
  • Oct 13, 2022Dividend: 1.41
  • Jan 12, 2023Dividend: 1.48
  • Apr 13, 2023Dividend: 1.48
  • Jul 13, 2023Dividend: 1.48
  • Jul 14, 2023Dividend: 1.48
  • Oct 12, 2023Dividend: 1.48
  • Jan 12, 2024Dividend: 1.55
  • Jan 15, 2024Dividend: 1.55
  • Apr 12, 2024Dividend: 1.55
  • Jul 15, 2024Dividend: 1.55
  • Oct 15, 2024Dividend: 1.55
  • Jan 15, 2025Dividend: 1.64
  • Apr 15, 2025Dividend: 1.64
  • Jul 15, 2025Dividend: 1.64
  • Oct 15, 2025Dividend: 1.64
  • Oct 31, 2025Earnings: 1.86; estimate 1.77; surprise 5.08%
  • Jan 16, 2026Dividend: 1.73
  • Feb 4, 2026Earnings: 2.71; estimate 2.65; surprise 2.26%
  • Apr 15, 2026Dividend: 1.73
  • Apr 29, 2026Earnings: 2.65; estimate 2.59; surprise 2.32%
  • Jul 15, 2026Dividend: 1.73
  • Jul 31, 2026Earnings: 3.65; estimate 3.61; surprise 1.11%
  • Oct 8, 2026Rating: JP Morgan · Overweight → Overweight
  • Oct 9, 2026Rating: Guggenheim · Buy → Buy
  • Oct 9, 2026Rating: UBS · Neutral → Neutral
  • Oct 13, 2026Rating: RBC Capital · Outperform → Outperform
  • Oct 15, 2026Dividend: 1.73
  • Oct 21, 2026Rating: Barclays · Overweight → Overweight
  • Oct 23, 2026Rating: Goldman Sachs · Neutral → Neutral
  • Oct 30, 2026Earnings: 3.82; estimate 3.73; surprise 2.41%
Signals (97)
NameDateAgo
RSI: OverboughtOct 12, 20262 weeks ago
SMA: BullishJun 22, 20264 months ago
SMA: BearishJun 15, 20264 months ago
SMA: BullishJun 1, 20265 months ago
MACD: Buy SignalJun 1, 20265 months ago
SMA: BullishMay 11, 20265 months ago
SMA: BearishMar 9, 20267 months ago
SMA: BearishMar 9, 20267 months ago
SMA: BullishFeb 9, 20268 months ago
SMA: BullishJan 19, 20269 months ago
SMA: BearishJan 12, 20269 months ago
SMA: BearishJan 5, 202610 months ago
SMA: BullishDec 15, 202510 months ago
SMA: BearishDec 1, 202511 months ago
MACD: Sell SignalDec 1, 202511 months ago
SMA: BullishNov 10, 202511 months ago
SMA: BearishOct 27, 20251 year ago
RSI: OverboughtSep 29, 20251 year ago
RSI: OverboughtSep 15, 20251 year ago
MACD: Buy SignalJul 21, 20251 year ago
SMA: BullishJun 30, 20251 year ago
SMA: BullishJun 30, 20251 year ago
SMA: BearishJun 16, 20251 year ago
SMA: BearishJun 16, 20251 year ago
SMA: BullishJun 2, 20251 year ago
SMA: BullishJun 2, 20251 year ago
SMA: BearishMay 5, 20251 year ago
SMA: BearishMay 5, 20251 year ago
SMA: BullishApr 28, 20251 year ago
SMA: BullishApr 28, 20251 year ago
MACD: Sell SignalApr 7, 20251 year ago
SMA: BearishMar 31, 20251 year ago
SMA: BearishMar 31, 20251 year ago
MACD: Buy SignalFeb 10, 20251 year ago
SMA: BullishFeb 3, 20251 year ago
SMA: BullishJan 27, 20251 year ago
SMA: BearishDec 2, 20241 year ago
SMA: BullishNov 25, 20241 year ago
SMA: BearishNov 11, 20241 year ago
SMA: BearishNov 11, 20241 year ago
SMA: BullishOct 28, 20242 years ago
MACD: Sell SignalOct 14, 20242 years ago
SMA: BearishOct 7, 20242 years ago
RSI: OverboughtAug 12, 20242 years ago
MACD: Buy SignalJul 22, 20242 years ago
SMA: BullishJul 8, 20242 years ago
SMA: BearishJul 1, 20242 years ago
SMA: BullishJun 3, 20242 years ago
SMA: BullishJun 3, 20242 years ago
SMA: BearishMay 20, 20242 years ago
SMA: BullishMay 13, 20242 years ago
SMA: BearishMay 6, 20242 years ago
SMA: BullishApr 29, 20242 years ago
SMA: BearishApr 22, 20242 years ago
MACD: Sell SignalApr 8, 20242 years ago
SMA: BearishApr 1, 20242 years ago
RSI: OverboughtJan 29, 20242 years ago
RSI: OverboughtJan 15, 20242 years ago
MACD: Buy SignalDec 11, 20232 years ago
SMA: BullishDec 4, 20232 years ago
SMA: BullishNov 27, 20232 years ago
MACD: Sell SignalOct 23, 20233 years ago
SMA: BearishOct 16, 20233 years ago
SMA: BearishSep 25, 20233 years ago
SMA: BullishAug 28, 20233 years ago
SMA: BearishAug 21, 20233 years ago
SMA: BullishAug 7, 20233 years ago
SMA: BearishJul 31, 20233 years ago
SMA: BullishJul 24, 20233 years ago
MACD: Buy SignalJul 24, 20233 years ago
SMA: BullishJul 17, 20233 years ago
SMA: BearishApr 24, 20233 years ago
SMA: BearishApr 24, 20233 years ago
MACD: Sell SignalApr 24, 20233 years ago
MACD: Buy SignalMar 27, 20233 years ago
SMA: BullishMar 13, 20233 years ago
SMA: BullishMar 13, 20233 years ago
SMA: BearishMar 6, 20233 years ago
SMA: BearishMar 6, 20233 years ago
SMA: BullishFeb 27, 20233 years ago
SMA: BullishFeb 6, 20233 years ago
SMA: BearishJan 23, 20233 years ago
MACD: Sell SignalJan 16, 20233 years ago
SMA: BearishJan 9, 20233 years ago
SMA: BullishNov 7, 20223 years ago
SMA: BearishOct 31, 20224 years ago
MACD: Buy SignalOct 31, 20224 years ago
SMA: BullishOct 24, 20224 years ago
SMA: BullishOct 10, 20224 years ago
SMA: BearishSep 26, 20224 years ago
SMA: BullishSep 12, 20224 years ago
SMA: BearishJul 18, 20224 years ago
SMA: BearishJul 18, 20224 years ago
SMA: BullishJun 20, 20224 years ago
SMA: BullishJun 20, 20224 years ago
SMA: BearishJun 6, 20224 years ago
SMA: BearishApr 18, 20224 years ago

Key statistics

Market cap
519.48B
Enterprise value
578.22B
Trailing P/E
83.04
Forward P/E
18.15
PEG ratio
0.59
Price / sales
8.07
Price / book
0.00
EPS (TTM)
3.54
Beta
0.23
Dividend yield
2.38%
Payout ratio
190.40%
Profit margin
9.80%
Revenue (TTM)
64.39B
Revenue growth
10.20%
Free cash flow
16.87B
Total cash
6.57B
Total debt
70.88B
Return on equity
0.00%
Shares outstanding
1.77B
Short % of float
0.98%
50-day average
268.63
200-day average
236.73

Analyst view

Consensus: buy

Buy
Price target (mean) 283.19 -4.0% downside
Target (low)
200.00
Target (mean)
283.19
Target (high)
325.00
Ratings (0m) 29 23 buy · 5 hold · 1 sell
  • Strong buy7
  • Buy16
  • Hold5
  • Sell0
  • Strong sell1

Next earnings

Feb 3, 2027

Expected Feb 3, 2027. Consensus EPS estimate 3.89.

Earnings history

Financials — quick view

All financials
ABBV Revenue — quarterly 16.99B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ABBV Net income — quarterly 3.61B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ABBV EPS — quarterly 2.04
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ABBV recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 3, 2027Dec 30, 20263.90———
Oct 30, 2026Sep 30, 20263.733.82+0.09+2.41%
Jul 31, 2026Jun 30, 20263.613.65+0.04+1.11%
Apr 29, 2026Mar 31, 20262.592.65+0.06+2.32%
Feb 4, 2026Dec 31, 20252.652.71+0.06+2.26%
Oct 31, 2025Sep 30, 20251.771.86+0.09+5.08%

Upgrades / downgrades

ABBV analyst upgrades and downgrades
DateFirmActionFromTo
Oct 23, 2026Goldman SachsmainNeutralNeutral
Oct 21, 2026BarclaysmainOverweightOverweight
Oct 13, 2026RBC CapitalreitOutperformOutperform
Oct 9, 2026UBSmainNeutralNeutral
Oct 9, 2026GuggenheimreitBuyBuy
Oct 8, 2026JP MorganmainOverweightOverweight

About AbbVie Inc.

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Website
abbvie.com

News

Your note

Sign in to keep a note on ABBV — it syncs with the Stock Master app.

Insider holders

ABBV insider holders
InsiderRelationLatest transactionDateShares held
DONOGHOE NICHOLASOfficerSaleAug 13, 202674,430
FREYMAN THOMAS CDirectorStock Award(Grant)May 7, 2026135,751
GONZALEZ RICHARD ADirectorStock GiftMar 30, 2025386,479
MICHAEL ROBERT A.Chief Executive OfficerStock Award(Grant)Feb 17, 2026215,260
RAPP EDWARD JDirectorStock Award(Grant)May 7, 202645,964
REENTS SCOTT T.Chief Financial OfficerStock Award(Grant)Feb 17, 202660,415

Institution ownership

ABBV institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.46%149,488,41243.95BJun 29, 2026
Vanguard Capital Management LLC6.53%115,396,09833.92BJun 29, 2026
State Street Corporation4.67%82,596,74824.28BJun 29, 2026
Vanguard Portfolio Management LLC2.74%48,477,99614.25BJun 29, 2026
JPMORGAN CHASE & CO2.71%47,862,79614.07BJun 29, 2026
Geode Capital Management, LLC2.66%46,998,43313.82BJun 29, 2026

Fund ownership

ABBV fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%56,090,16716.49BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%45,784,61413.46BJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%23,546,1256.92BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.30%22,934,5676.74BAug 30, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.24%21,857,3566.43BSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Value Index Fund0.95%16,815,7644.94BJun 29, 2026
Advertisement